Cyagen Biosciences

With the gradual improvement of the COVID-19 situation in China in the past few days, along with a worsening situation across many regions, research on vaccines and related antiviral drugs has become a key issue for most people both inside and outside the life science research industry. However, the vaccine research and development (R&D) process is long and complex, especially considering the need for drugs to undergo time-consuming clinical trials. A large number of animal models are urgently needed to verify the efficacy and safety of new compounds before human trials. As an upstream industry for vaccine and drug R&D, what kind of effects will this pandemic have on the animal model field and associated life science research? We explore this issue in-depth with our Chief Scientific Officer, Dr. Marvin Ouyang.   Dr. Marvin Ouyang    Executive VP and Chief Scientific Officer, Cyage...

The suicidal response of Immune system to the SARS-CoV-2   Since COVID-19 poses a significant threat to public health and also represents a challenge for antiviral drug development and administration globally, current efforts focus on prevention and control while accelerating the research on the SARS-CoV-2 coronavirus, which has caused the outbreak of COVID-19. So far, studies on the epidemiological and clinical characteristics of this illness is still growing, but there is significant anecdotal evidence of value. Most patients suffering from COVID-19 were observed with symptoms like fever, cough, and diarrhea, but also some express serious complications such as acute respiratory failure, acute respiratory distress, and septic shock. The "COVID-19 Diagnosis and Treatment Program (6th Edition)" issued by the National Health Commission of the People’s Republic of China, mentioned the clinical warning indicators for the diagnosis and treatment of patients with severe and critica...